Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...

According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a ...

Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and ...

while Pneumovax 23 (pneumococcal vaccine polyvalent) vaccine sales declined 12% to $74 million. Sales of Vaxneuvance, Merck’s pneumococcal 15-valent conjugate vaccine, were $161 million ...